HUP0600103A2 - Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders - Google Patents
Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disordersInfo
- Publication number
- HUP0600103A2 HUP0600103A2 HU0600103A HUP0600103A HUP0600103A2 HU P0600103 A2 HUP0600103 A2 HU P0600103A2 HU 0600103 A HU0600103 A HU 0600103A HU P0600103 A HUP0600103 A HU P0600103A HU P0600103 A2 HUP0600103 A2 HU P0600103A2
- Authority
- HU
- Hungary
- Prior art keywords
- administration
- cyclic
- treatment
- receptor agonist
- associated disorders
- Prior art date
Links
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 title 1
- 229940117029 Melanocortin receptor agonist Drugs 0.000 title 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 title 1
- 238000011260 co-administration Methods 0.000 title 1
- 229940095074 cyclic amp Drugs 0.000 title 1
- 239000000336 melanocortin receptor agonist Substances 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27320601P | 2001-03-02 | 2001-03-02 | |
US27329101P | 2001-03-02 | 2001-03-02 | |
US28971901P | 2001-05-09 | 2001-05-09 | |
PCT/US2002/006805 WO2002069905A2 (en) | 2001-03-02 | 2002-03-04 | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0600103A2 true HUP0600103A2 (en) | 2006-06-28 |
Family
ID=27402538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0600103A HUP0600103A2 (en) | 2001-03-02 | 2002-03-04 | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030069169A1 (hu) |
EP (1) | EP1370211A4 (hu) |
JP (1) | JP2005506286A (hu) |
CA (1) | CA2439691A1 (hu) |
HU (1) | HUP0600103A2 (hu) |
WO (1) | WO2002069905A2 (hu) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
BR0213100A (pt) | 2001-10-05 | 2004-11-30 | Combinatorx Inc | Combinações para o tratamento de distúrbios imuniinflamatórios |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
US20040010010A1 (en) * | 2002-04-30 | 2004-01-15 | Ebetino Frank Hallock | Melanocortin receptor ligands |
US20040001895A1 (en) * | 2002-06-17 | 2004-01-01 | Pfizer Inc. | Combination treatment for depression and anxiety |
US20030235631A1 (en) * | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
AU2003248888A1 (en) * | 2002-07-09 | 2004-01-23 | Palatin Technologies, Inc. | Peptide composition for treatment of sexual dysfunction |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
WO2004110424A1 (en) * | 2003-05-28 | 2004-12-23 | Glaxo Group Limited | Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal |
WO2005018563A2 (en) * | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
JP2007504201A (ja) * | 2003-09-05 | 2007-03-01 | アルタナ ファルマ アクチエンゲゼルシャフト | 真性糖尿病の治療のためのpde4阻害剤の使用 |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
KR20050045927A (ko) * | 2003-11-12 | 2005-05-17 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
US7550602B1 (en) * | 2004-01-14 | 2009-06-23 | Palatin Technologies, Inc. | Small molecule compositions for sexual dysfunction |
US6974187B2 (en) * | 2004-01-28 | 2005-12-13 | Tachi-S Co., Ltd. | Vehicle seat structure |
WO2006073413A1 (en) * | 2004-02-20 | 2006-07-13 | The Board Of Trustees Of The University Of Illinois | Blood pressure reduction in salt-sensitive |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
CN102600144A (zh) * | 2005-03-08 | 2012-07-25 | 奈科明有限责任公司 | 治疗糖尿病的罗氟司特 |
WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
EA200702208A1 (ru) * | 2005-04-22 | 2008-04-28 | Алантос Фармасьютиклз Холдинг, Инк. | Ингибиторы дипептидилпептидазы-iv |
EA013646B1 (ru) | 2005-05-25 | 2010-06-30 | Басф Акциенгезельшафт | Замещённые бензоилом серин-амиды |
EP1888532A1 (de) | 2005-05-25 | 2008-02-20 | Basf Aktiengesellschaft | Heteroaroylsubstituierte serin-amide |
WO2007139753A2 (en) * | 2006-05-22 | 2007-12-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
US20080207659A1 (en) * | 2007-02-15 | 2008-08-28 | Asit Kumar Chakraborti | Inhibitors of phosphodiesterase type 4 |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
CN101917992A (zh) * | 2007-03-27 | 2010-12-15 | 奥默罗斯公司 | 用于治疗运动障碍的pde7抑制剂的用途 |
FR2915100B1 (fr) * | 2007-04-19 | 2009-06-05 | Sanofi Aventis Sa | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson |
FR2915098B1 (fr) | 2007-04-19 | 2009-06-05 | Sanofi Aventis Sa | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere |
FR2915099B1 (fr) | 2007-04-19 | 2009-06-05 | Sanofi Aventis Sa | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens |
EP2203174A4 (en) * | 2007-09-19 | 2010-09-29 | Combinatorx Inc | THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS |
MX2010006724A (es) * | 2007-12-17 | 2010-09-07 | Combinatorx Inc | Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. |
FR2937972B1 (fr) * | 2008-11-04 | 2013-03-29 | Galderma Res & Dev | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
FR2937868B1 (fr) | 2008-11-04 | 2010-11-05 | Galderma Res & Dev | Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
WO2012131090A1 (en) | 2011-03-31 | 2012-10-04 | Galderma Research & Development | Method for treatment of xeroderma pigmentosum |
KR20150087246A (ko) * | 2012-11-28 | 2015-07-29 | 사노피 | 4-(사이클로프로필메톡시)-n-(3,5-디클로로-1-옥시도-4-피리딜)-5-메톡시피리딘-2-카복스아미드의 제조 방법 |
US10232018B2 (en) | 2013-03-14 | 2019-03-19 | Mallinckrodt Ard Ip Limited | ACTH for treatment of acute respiratory distress syndrome |
CU24442B1 (es) * | 2014-04-04 | 2019-09-04 | X Rx Inc | Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina |
JP6236185B1 (ja) * | 2016-09-27 | 2017-11-22 | 丸善製薬株式会社 | 脳の機能改善剤および脳の機能改善用飲食品 |
CN108619090B (zh) * | 2018-05-30 | 2020-12-08 | 河北爱尔海泰制药有限公司 | 一种高稳定性盐酸奥普力农注射液组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0710109T3 (da) * | 1993-06-18 | 2005-01-03 | Smithkline Beecham Corp | Fremgangsmåde til identifikation af en PDE IV inhibitor |
WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
-
2002
- 2002-03-04 HU HU0600103A patent/HUP0600103A2/hu unknown
- 2002-03-04 CA CA002439691A patent/CA2439691A1/en not_active Abandoned
- 2002-03-04 JP JP2002569083A patent/JP2005506286A/ja active Pending
- 2002-03-04 US US10/090,258 patent/US20030069169A1/en not_active Abandoned
- 2002-03-04 WO PCT/US2002/006805 patent/WO2002069905A2/en not_active Application Discontinuation
- 2002-03-04 EP EP02713772A patent/EP1370211A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2002069905A2 (en) | 2002-09-12 |
EP1370211A4 (en) | 2005-02-09 |
WO2002069905A3 (en) | 2003-10-09 |
US20030069169A1 (en) | 2003-04-10 |
EP1370211A2 (en) | 2003-12-17 |
JP2005506286A (ja) | 2005-03-03 |
CA2439691A1 (en) | 2002-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0600103A2 (en) | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders | |
IL155225A0 (en) | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders | |
HK1079426A1 (en) | Use of ikappab kinase inhibitors for the treatment of pain | |
HUP0302544A3 (en) | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors | |
AU2002351397A8 (en) | Systems and methods using vasoconstriction for improved thermal treatment of tissues | |
IL208191A0 (en) | Compositions and methods for treating rage-associated disorders | |
HK1094909A1 (en) | Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18 | |
AU2003223579A8 (en) | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease | |
EP1489915A4 (en) | TREATMENT AND PREVENTION OF INFLAMMATORY DISORDERS | |
PL361947A1 (en) | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for treating of nervous systems disorders | |
HUP0501017A2 (en) | Methods and compositions for treatment of central nervous system disorders | |
SI1627639T1 (sl) | Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj | |
PL368556A1 (en) | Methods for treating or preventing skin disorders using cd2-binding agents | |
HK1154504A1 (en) | Chemokine receptor antagonists and methods of use thereof | |
AU2003210983A8 (en) | Kinase inhibitors and methods of use thereof | |
AU2002339673A1 (en) | Agonists and antagonists of ryzn for the treatment of metabolic disorders | |
EP1425020A4 (en) | METHOD AND COMPOSITIONS FOR TREATING APOPTOSIS-RELATED DISEASES | |
AU2000270300A1 (en) | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders | |
HK1062806A1 (en) | Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors | |
IL142102A0 (en) | Zinc-sensing receptor and methods of treatment of disorders associated herewith | |
AU2002366272A8 (en) | Edg-receptor agonist for the treatment of hypertension | |
SI1478380T1 (sl) | Uporaba inhibitorjev tirozin kinaze za zdravljenje bolezni CZS | |
AU2002339683A1 (en) | Agonist and antagonists of redax for the treatment of metabolic disorders | |
AU2002339680A1 (en) | Agonists and antagonists of bromix for the treatment of metabolic disorders | |
AU2002321761A1 (en) | Agonists and antagonists of disomet for the treatment of metabolic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |